Skip to main content
. 2021 Dec 29;2021:5177488. doi: 10.1155/2021/5177488

Figure 7.

Figure 7

circFAT1 acting as a miRNA sponge for miR-4781-3p by targeting SMAD5. (a) I: Dual-luciferase reporter gene assay was used to verify the binding sites between circFAT1 and miR-4781-3p. II: Dual-luciferase reporter gene assay was used to verify the binding sites between SMAD5 and miR-4781-3p. (b) Rescue experiment results showed that miR-4781 inhibitor could reverse the inhibition of circFAT1 siRNA on the osteogenic ability of PDLSCs. The expression level of SMAD5 was also reversed by miR-4781 inhibitor. (c) After seven days, less expression of ALP was found in the si-FAT1 group and si-FAT1 + miR-4781 iNC group, while the expression of ALP increased in the si-FAT1 + inhibitor group. The mineralization nodules in the si-FAT1 group and si-FAT1 + miR-4781 iNC group decreased. (d) I: ALP activity showed the same trend. II: Mineralized nodules were significantly increased in the si-FAT1 + inhibitor group, and calcium content was significantly increased (P < 0.001). (e) FISH experiments proved that circFAT1 were mostly located in the cytoplasm, 18S and U6 were the internal control. (Scale bar: 25 μm). ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001.